Fixed-dose combination bictegravir, emtricitabine, and tenofovir alafenamide in adolescents and children with HIV: week 48 results of a single-arm, open-label, multicentre, phase 2/3 trial

Renal safety of tenofovir alafenamide vs tenofovir disoproxil fumarate

(2019) Samir K. Gupta et al.   AIDS

Disparities in HIV Viral Suppression Among Adolescents and Young Adults by Perinatal Infection

(2019) Kunjal Patel et al.   AMERICAN JOURNAL OF PUBLIC HEALTH

Co-formulated bictegravir, emtricitabine, and tenofovir alafenamide versus dolutegravir with emtricitabine and tenofovir alafenamide for initial treatment of HIV-1 infection: week 96 results from a randomised, double-blind, multicentre, phase 3, non-inferiority trial

(2019) Hans-Jürgen Stellbrink et al.   Lancet HIV

Bictegravir combined with emtricitabine and tenofovir alafenamide versus dolutegravir, abacavir, and lamivudine for initial treatment of HIV-1 infection: week 96 results from a randomised, double-blind, multicentre, phase 3, non-inferiority trial

(2019) David A Wohl et al.   Lancet HIV

Treatment Adherence And Persistence Among HIV-1 Patients Newly Starting Treatment

(2019) Dionne M. Hines et al.   Patient Preference and Adherence

Growth and pubertal development in HIV-infected adolescents

(2018) Paige L. Williams et al.   Current Opinion in HIV and AIDS

Antiretroviral Drugs for Treatment and Prevention of HIV Infection in Adults

(2018) Michael S. Saag et al.   JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION

Brief Report

(2017) José R. Arribas et al.   JAIDS-JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES

Antiviral Activity, Safety, and Pharmacokinetics of Bictegravir as 10-Day Monotherapy in HIV-1–Infected Adults

(2017) Joel E. Gallant et al.   JAIDS-JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES

Coformulated bictegravir, emtricitabine, and tenofovir alafenamide versus dolutegravir with emtricitabine and tenofovir alafenamide, for initial treatment of HIV-1 infection (GS-US-380–1490): a randomised, double-blind, multicentre, phase 3, non-inferiority trial

(2017) Paul E Sax et al.   LANCET

Bictegravir, emtricitabine, and tenofovir alafenamide versus dolutegravir, abacavir, and lamivudine for initial treatment of HIV-1 infection (GS-US-380-1489): a double-blind, multicentre, phase 3, randomised controlled non-inferiority trial

(2017) Joel Gallant et al.   LANCET

Bictegravir versus dolutegravir, each with emtricitabine and tenofovir alafenamide, for initial treatment of HIV-1 infection: a randomised, double-blind, phase 2 trial

(2017) Paul E Sax et al.   Lancet HIV

Antiviral Activity of Bictegravir (GS-9883), a Novel Potent HIV-1 Integrase Strand Transfer Inhibitor with an Improved Resistance Profile

(2016) Manuel Tsiang et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

Adherence to antiretroviral therapy in adolescents living with HIV

(2014) Sung-Hee Kim et al.   AIDS

The Adolescent and Young Adult HIV Cascade of Care in the United States: Exaggerated Health Disparities

(2014) Brian C. Zanoni et al.   AIDS PATIENT CARE AND STDS

Growth among HIV-infected Children Receiving Antiretroviral Therapy in Dar es Salaam, Tanzania

(2014) R. S. Mwiru et al.   JOURNAL OF TROPICAL PEDIATRICS

Adherence to Antiretroviral Medications for HIV Pre-Exposure Prophylaxis

(2012) Linda J. Koenig et al.   AMERICAN JOURNAL OF PREVENTIVE MEDICINE

A Meta-analysis to Assess the FDA DAVP's TLOVR Algorithm in HIV Submissions

(2012) Fraser Smith et al.   DRUG INFORMATION JOURNAL